E-LIB Suche - Ergebnisse für: Eroglu, Zeynep

1

Phase 2 open-label, multicenter, single-arm study of cemipl..:

Stratigos, Alexander J. ; Sekulic, Aleksandar ; Peris, Ketty...
Journal of the American Academy of Dermatology. 90 (2024) 2 - p. 414-418 , 2024

Link: https://doi.org/10.1016/..

2

First-in-Human Stage III/IV Melanoma Clinical Trial of Immu..:

Markowitz, Joseph ; Shamblott, Michael ; Brohl, Andrew S....
Molecular Cancer Therapeutics. , 2024

Link: https://doi.org/10.1158/..

3

Health-Related Quality of Life in Patients with Metastatic ..:

Lewis, Karl D ; Inocencio, Timothy J ; Quek, Ruben GW...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s337 , 2024

Link: https://doi.org/10.25251..

4

Patient reported outcomes and patient experiences of immune..:

Tometich, Danielle B. ; Geiss, Carley ; Maconi, Melinda L....
Supportive Care in Cancer. 32 (2024) 6 - p. , 2024

Link: https://doi.org/10.1007/..

5

Efficacy and toxicity of adjuvant radiotherapy in recurrent..:

Bhave, Prachi ; Hong, Angela ; Lo, Serigne N...
Journal for ImmunoTherapy of Cancer. 11 (2023) 3 - p. e006629 , 2023

Link: https://doi.org/10.1136/..

6

Phase 2 study of cemiplimab in patients with locally advanc..:

Stratigos, Alexander J ; Sekulic, Aleksandar ; Peris, Ketty...
SKIN The Journal of Cutaneous Medicine. 7 (2023) 2 - p. s178 , 2023

Link: https://doi.org/10.25251..

7

Ipilimumab with or without nivolumab in PD-1 or PD-L1 block..:

VanderWalde, Ari ; Bellasea, Shay L. ; Kendra, Kari L....
Nature Medicine. 29 (2023) 9 - p. 2278-2285 , 2023

Link: https://doi.org/10.1038/..

8

Primary analysis of Phase 2 results for cemiplimab in patie..:

Lewis, Karl D ; Peris, Ketty ; Sekulic, Aleksandar...
SKIN The Journal of Cutaneous Medicine. 7 (2023) 2 - p. s177 , 2023

Link: https://doi.org/10.25251..

9

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous..:

Marin-Acevedo, Julian A. ; Withycombe, Bethany M. ; Kim, Youngchul...
Cancers. 15 (2023) 12 - p. 3180 , 2023

Link: https://doi.org/10.3390/..

10

Efficacy of ipilimumab 3 mg/kg following progression on low..:

Lai-Kwon, Julia ; Jacques, Sarah ; Carlino, Matteo...
European Journal of Cancer. 186 (2023) - p. 12-21 , 2023

Link: https://doi.org/10.1016/..

11

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in..:

Eroglu, Zeynep ; Chen, Y. Ann ; Smalley, Inna...
Cancer. 130 (2023) 2 - p. 232-243 , 2023

Link: https://doi.org/10.1002/..

12

Circulating tumor DNA‐based molecular residual disease dete..:

Eroglu, Zeynep ; Krinshpun, Shifra ; Kalashnikova, Ekaterina...
Cancer. 129 (2023) 11 - p. 1723-1734 , 2023

Link: https://doi.org/10.1002/..

13

Combined nivolumab and ipilimumab with or without stereotac..:

Kim, Sungjune ; Wuthrick, Evan ; Blakaj, Dukagjin...
The Lancet. 400 (2022) 10357 - p. 1008-1019 , 2022

Link: https://doi.org/10.1016/..

14

Combination targeted and immune therapy in the treatment of..:

Bari, Shahla ; Muzaffar, Jameel ; Eroglu, Zeynep
Therapeutic Advances in Medical Oncology. 14 (2022) - p. 175883592210903 , 2022

Link: https://doi.org/10.1177/..

15

Phase II clinical and immune correlate study of adjuvant ni..:

Khushalani, Nikhil I ; Vassallo, Melinda ; Goldberg, Judith D...
Journal for ImmunoTherapy of Cancer. 10 (2022) 11 - p. e005684 , 2022

Link: https://doi.org/10.1136/..